Foghorn Therapeutics Stock Net Income
| FHTX Stock | USD 6.20 0.12 1.97% |
As of the 22nd of January, Foghorn Therapeutics shows the Downside Deviation of 4.93, mean deviation of 4.12, and Coefficient Of Variation of 678.3. Foghorn Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Foghorn Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Foghorn Therapeutics' valuation are provided below:Foghorn Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn Therapeutics. If investors know Foghorn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Foghorn Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Foghorn Therapeutics is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Foghorn Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn Therapeutics' market value can be influenced by many factors that don't directly affect Foghorn Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Foghorn Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Foghorn Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Foghorn Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Foghorn Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Foghorn Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Foghorn Therapeutics.
| 10/24/2025 |
| 01/22/2026 |
If you would invest 0.00 in Foghorn Therapeutics on October 24, 2025 and sell it all today you would earn a total of 0.00 from holding Foghorn Therapeutics or generate 0.0% return on investment in Foghorn Therapeutics over 90 days. Foghorn Therapeutics is related to or competes with Immuneering Corp, Pyxis Oncology, Assembly Biosciences, Zura Bio, Arcturus Therapeutics, Sagimet Biosciences, and Humacyte. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting geneti... More
Foghorn Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Foghorn Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Foghorn Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.93 | |||
| Information Ratio | 0.1294 | |||
| Maximum Drawdown | 31.12 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 9.16 |
Foghorn Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Foghorn Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Foghorn Therapeutics' standard deviation. In reality, there are many statistical measures that can use Foghorn Therapeutics historical prices to predict the future Foghorn Therapeutics' volatility.| Risk Adjusted Performance | 0.1176 | |||
| Jensen Alpha | 0.7143 | |||
| Total Risk Alpha | 0.1061 | |||
| Sortino Ratio | 0.1517 | |||
| Treynor Ratio | 0.6216 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Foghorn Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Foghorn Therapeutics January 22, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1176 | |||
| Market Risk Adjusted Performance | 0.6316 | |||
| Mean Deviation | 4.12 | |||
| Semi Deviation | 4.35 | |||
| Downside Deviation | 4.93 | |||
| Coefficient Of Variation | 678.3 | |||
| Standard Deviation | 5.78 | |||
| Variance | 33.36 | |||
| Information Ratio | 0.1294 | |||
| Jensen Alpha | 0.7143 | |||
| Total Risk Alpha | 0.1061 | |||
| Sortino Ratio | 0.1517 | |||
| Treynor Ratio | 0.6216 | |||
| Maximum Drawdown | 31.12 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 9.16 | |||
| Downside Variance | 24.3 | |||
| Semi Variance | 18.9 | |||
| Expected Short fall | (4.88) | |||
| Skewness | 0.8267 | |||
| Kurtosis | 3.85 |
Foghorn Therapeutics Backtested Returns
Foghorn Therapeutics appears to be unstable, given 3 months investment horizon. Foghorn Therapeutics secures Sharpe Ratio (or Efficiency) of 0.15, which denotes the company had a 0.15 % return per unit of risk over the last 3 months. By reviewing Foghorn Therapeutics' technical indicators, you can evaluate if the expected return of 0.85% is justified by implied risk. Please utilize Foghorn Therapeutics' Downside Deviation of 4.93, mean deviation of 4.12, and Coefficient Of Variation of 678.3 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Foghorn Therapeutics holds a performance score of 11. The firm shows a Beta (market volatility) of 1.35, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Foghorn Therapeutics will likely underperform. Please check Foghorn Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Foghorn Therapeutics' price patterns will revert.
Auto-correlation | 0.35 |
Below average predictability
Foghorn Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Foghorn Therapeutics time series from 24th of October 2025 to 8th of December 2025 and 8th of December 2025 to 22nd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Foghorn Therapeutics price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Foghorn Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.35 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.43 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Foghorn Therapeutics reported net income of (86.62 Million). This is 125.38% lower than that of the Biotechnology sector and 223.66% lower than that of the Health Care industry. The net income for all United States stocks is 115.17% higher than that of the company.
Foghorn Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Foghorn Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics of similar companies.Foghorn Therapeutics is currently under evaluation in net income category among its peers.
Foghorn Fundamentals
| Return On Equity | -4.7 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (2.94) % | |||
| Operating Margin | (2.27) % | |||
| Current Valuation | 168.55 M | |||
| Shares Outstanding | 58.58 M | |||
| Shares Owned By Insiders | 18.03 % | |||
| Shares Owned By Institutions | 70.09 % | |||
| Number Of Shares Shorted | 1.13 M | |||
| Price To Book | 10.71 X | |||
| Price To Sales | 13.31 X | |||
| Revenue | 22.6 M | |||
| Gross Profit | (59.41 M) | |||
| EBITDA | (97.17 M) | |||
| Net Income | (86.62 M) | |||
| Cash And Equivalents | 373.5 M | |||
| Cash Per Share | 8.94 X | |||
| Total Debt | 37.13 M | |||
| Debt To Equity | 2.19 % | |||
| Current Ratio | 6.84 X | |||
| Book Value Per Share | (1.59) X | |||
| Cash Flow From Operations | (100.41 M) | |||
| Short Ratio | 7.00 X | |||
| Earnings Per Share | (1.14) X | |||
| Target Price | 11.67 | |||
| Number Of Employees | 112 | |||
| Beta | 3.05 | |||
| Market Capitalization | 326.3 M | |||
| Total Asset | 283.98 M | |||
| Retained Earnings | (558.18 M) | |||
| Working Capital | 182.61 M | |||
| Net Asset | 283.98 M |
About Foghorn Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Foghorn Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.